Three classes of anticholinergic drugs carry the strongest links to dementia: antidepressants, bladder medications, and Parkinson’s drugs. People diagnosed with dementia were up to 30% more likely to have been prescribed anticholinergic medications in these categories, and the risk increases with higher doses and longer use.
How These Drugs Affect the Brain
Anticholinergic drugs work by blocking acetylcholine, a chemical messenger involved in muscle contractions, digestion, and many other body functions. The problem is that acetylcholine also plays a central role in memory and learning. When these drugs block it in the brain, they disrupt the normal processing of genetic instructions in memory-related brain regions, producing changes that look strikingly similar to what happens in Alzheimer’s disease.
Specifically, blocking acetylcholine leads to abnormal processing of a gene involved in creating amyloid proteins. In lab studies, this resulted in a tenfold increase in soluble amyloid proteins in the brain’s memory center, the same toxic buildup that defines Alzheimer’s. Researchers also observed increased brain cell death, loss of connections between neurons, and measurable cognitive decline.
The Highest-Risk Prescription Drugs
Not all anticholinergic drugs carry equal risk. Researchers at Indiana University developed the Anticholinergic Cognitive Burden (ACB) scale, which scores medications from 1 to 3 based on how strongly they affect the brain. Drugs scoring a 3 have the clearest evidence of causing confusion, delirium, and long-term cognitive problems. These are the ones most strongly tied to dementia.
The most frequently prescribed high-risk drugs fall into three categories:
- Antidepressants: Amitriptyline, dosulepin, and paroxetine. These are older-style antidepressants (tricyclics and one older SSRI) with strong anticholinergic activity.
- Bladder medications: Oxybutynin, tolterodine, and solifenacin (Vesicare). These are commonly prescribed for overactive bladder and urinary incontinence.
- Parkinson’s drugs: Procyclidine (Kemadrin) and similar medications used to manage tremor and muscle stiffness.
A large BMJ study found a clear dose-response pattern for all three categories: the more of these drugs a person took over time, the higher their dementia risk. Even use of fewer than 90 defined daily doses showed a smaller but noticeable association with dementia.
Over-the-Counter Drugs That Count
Some of the most widely used anticholinergic drugs don’t require a prescription. Diphenhydramine, the active ingredient in Benadryl and many over-the-counter sleep aids (like ZzzQuil and Tylenol PM), has significant anticholinergic activity. A study published in JAMA Internal Medicine found that long-term use of diphenhydramine and similar first-generation antihistamines was linked to increased dementia risk.
This matters because many people take these medications regularly for allergies or sleep without thinking of them as anything more than a mild pill. If you use diphenhydramine often, newer antihistamines like loratadine (Claritin) or cetirizine (Zyrtec) are alternatives that don’t carry the same anticholinergic load.
How Much Use Is Dangerous
A landmark study tracking over 3,400 adults age 65 and older for a decade found that 78% of participants used anticholinergic drugs at least once during that period. Nearly a quarter of them developed dementia, usually Alzheimer’s. The higher the cumulative use, the higher the risk, regardless of whether the drugs had been taken recently or years earlier.
That last point is especially important. The BMJ study found that anticholinergic drugs prescribed 15 to 20 years before a dementia diagnosis were still significantly associated with greater dementia incidence. This wasn’t just a short-term fog that cleared after stopping the medication. The association persisted across decades, with a 17% increased risk even at that long a lag time.
The risk becomes most evident in people whose average anticholinergic burden score reaches 3 or higher. Taking multiple lower-scoring drugs can add up to the same total burden as a single high-scoring one, which is why clinicians are increasingly encouraged to look at a patient’s full medication list rather than evaluating each drug in isolation.
Is the Damage Reversible?
This is the question most people want answered, and the research is sobering. The data showing associations between anticholinergic use 15 to 20 years before diagnosis suggests that at least some of the risk is not easily undone. The biological mechanism supports this: if these drugs trigger a cascade of amyloid protein buildup and neuron death, those changes may be difficult to reverse once they’ve occurred.
That said, the dose-response relationship offers some reassurance. Lower cumulative exposure carries lower risk, which means reducing or stopping these drugs earlier likely limits the damage. Short-term or occasional use appears far less concerning than daily use sustained over months or years. The 2023 American Geriatrics Society Beers Criteria specifically recommends avoiding anticholinergic drugs in older adults with existing dementia or cognitive impairment, and minimizing the total number of anticholinergic drugs for everyone else.
Lower-Risk Alternatives
For overactive bladder, mirabegron (Myrbetriq) works through an entirely different mechanism. It relaxes the bladder muscle without blocking acetylcholine, allowing the bladder to hold more urine. Botox injections into the bladder muscle are another option for people who haven’t responded to other treatments, with benefits lasting several months. Behavioral therapies combined with medication tend to work better than medication alone.
For allergies, switching from diphenhydramine to a newer antihistamine like loratadine eliminates the anticholinergic exposure entirely. For sleep, the swap is harder since many OTC sleep aids rely on diphenhydramine, but non-anticholinergic options exist.
For depression, many modern antidepressants (SSRIs like sertraline or escitalopram, and SNRIs like duloxetine) have little to no anticholinergic activity compared to older tricyclics like amitriptyline. If you’re currently taking a tricyclic antidepressant, it’s worth discussing alternatives with whoever prescribes it, especially if you’ve been on it for years.
Checking Your Own Medication List
The anticholinergic burden is cumulative. A bladder drug scoring 3 on its own is concerning, but even a collection of medications each scoring 1 can add up to meaningful risk. Common score-1 drugs include some blood pressure medications, heartburn drugs, and muscle relaxants that most people wouldn’t think of as anticholinergic.
The ACB scale developed at Indiana University is publicly available and lists hundreds of medications with their scores. Reviewing your full medication list against it, including over-the-counter drugs and sleep aids, gives you a clearer picture of your total anticholinergic exposure than looking at any single prescription alone.